You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 4, 2024

GALLIUM GA-68 GOZETOTIDE - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for gallium ga-68 gozetotide and what is the scope of freedom to operate?

Gallium ga-68 gozetotide is the generic ingredient in three branded drugs marketed by Telix, Novartis, Univ Ca Los Angeles, and Univ Of Ca San Fran, and is included in four NDAs. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Gallium ga-68 gozetotide has ninety-one patent family members in twenty-one countries.

Four suppliers are listed for this compound.

Summary for GALLIUM GA-68 GOZETOTIDE
International Patents:91
US Patents:3
Tradenames:3
Applicants:4
NDAs:4
Finished Product Suppliers / Packagers: 4
Clinical Trials: 4
What excipients (inactive ingredients) are in GALLIUM GA-68 GOZETOTIDE?GALLIUM GA-68 GOZETOTIDE excipients list
DailyMed Link:GALLIUM GA-68 GOZETOTIDE at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for GALLIUM GA-68 GOZETOTIDE
Generic Entry Dates for GALLIUM GA-68 GOZETOTIDE*:
Constraining patent/regulatory exclusivity:
Dosage:
POWDER;INTRAVENOUS
Generic Entry Dates for GALLIUM GA-68 GOZETOTIDE*:
Constraining patent/regulatory exclusivity:
Dosage:
POWDER;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for GALLIUM GA-68 GOZETOTIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Novartis PharmaceuticalsPhase 3
Mayo ClinicPhase 3
Prostate Cancer FoundationPhase 1/Phase 2

See all GALLIUM GA-68 GOZETOTIDE clinical trials

Pharmacology for GALLIUM GA-68 GOZETOTIDE

US Patents and Regulatory Information for GALLIUM GA-68 GOZETOTIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Univ Of Ca San Fran GALLIUM GA 68 GOZETOTIDE gallium ga-68 gozetotide SOLUTION;INTRAVENOUS 212643-001 Dec 1, 2020 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Telix ILLUCCIX gallium ga-68 gozetotide POWDER;INTRAVENOUS 214032-001 Dec 17, 2021 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Univ Ca Los Angeles GALLIUM GA 68 GOZETOTIDE gallium ga-68 gozetotide SOLUTION;INTRAVENOUS 212642-001 Dec 1, 2020 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for GALLIUM GA-68 GOZETOTIDE

Country Patent Number Title Estimated Expiration
Japan 2021130675 放射性核種錯体を調製するための方法およびキット (METHODS AND KITS FOR PREPARING RADIONUCLIDE COMPLEXES) ⤷  Sign Up
Japan 2017530188 放射標識用キット ⤷  Sign Up
Canada 2696627 CONJUGUES LIGAND-LIEUR DE LIAISON AU PSMA ET PROCEDES POUR UTILISER CEUX-CI (PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.